SCHEMBL1017916

SCHEMBL1017916

Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3c(ncn3C)n2)c(OC(C)C)cc1C1CCN(C)CC1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 20/20 0.76
▸ INSR P06213 16/20 0.76
▸ KCNH2 Q12809 5/20 0.76
▸ NPM1 P06748 8/20 0.75
▸ ABL1 P00519 1/20 0.74
▸ EGFR P00533 1/20 0.74
▸ ERBB2 P04626 1/20 0.74
▸ LCK P06239 1/20 0.74
▸ RET P07949 1/20 0.74
▸ IGF1R P08069 1/20 0.74
▸ MET P08581 1/20 0.74
▸ PDGFRA P16234 1/20 0.74
▸ CDK2 P24941 1/20 0.74
▸ AKT1 P31749 1/20 0.74
▸ KDR P35968 1/20 0.74
▸ GSK3B P49841 1/20 0.74
▸ PLK1 P53350 1/20 0.74
▸ EPHB4 P54760 1/20 0.74
▸ BTK Q06187 1/20 0.74
▸ EML4 Q9HC35 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19921216 0.88 ALK (0.80) ALKINSRKCNH2NPM1ABL1
SCHEMBL1546085 0.87 ALK (1.00) ALKINSRKCNH2NPM1ABL1
SCHEMBL1949497 0.86 ALK (0.79) ALKINSRKCNH2NPM1ABL1
SCHEMBL1546090 0.85 ALK (1.00) ALKINSRKCNH2NPM1ABL1
SCHEMBL1546327 0.85 ALK (1.00) ALKINSRKCNH2NPM1ABL1
SCHEMBL29537500 0.84 ALK (1.00) ALKINSRKCNH2NPM1ABL1
SCHEMBL1545736 0.84 ALK (0.78) ALKINSRKCNH2NPM1ABL1
SCHEMBL1545609 0.84 ALK (1.00) ALKINSRKCNH2NPM1ABL1
SCHEMBL3958863 0.84 ALK (0.78) ALKINSRKCNH2NPM1ABL1
SCHEMBL21099671 0.83 ALK (0.80) ALKINSRKCNH2NPM1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2271630-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2016-03-23 — — EP claimed
EP-2271630-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2016-03-23 — — EP disclosed
EP-2271630-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2016-03-23 — — EP disclosed
US-8592432-B2 Compounds and compositions as protein kinase inhibitors NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2013-11-26 — — US disclosed
US-20110135668-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-06-09 — — US disclosed
US-20110135668-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-06-09 — — US disclosed
US-20110135668-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-06-09 — — US disclosed
EP-2271630-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-01-12 — — EP disclosed
WO-2009126515-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-10-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110135668-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS ROS1, INSR, IGF1R ALK 6/4885INSR 2/4885KCNH2 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback